in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Watson completes acquisition of Actavis for €4.25 billion
2:02 PM MST | November 8, 2012 | Deepti Ramesh
Watson Pharmaceuticals (Parsippany, NJ) says it has completed the previously announced acquisition of generic pharmaceuticals company Actavis (Zug, Switzerland) for €4.25 billion ($5.4 billion). The acquisition creates the world's third-largest generic pharmaceutical company, with anticipated pro forma combined 2012 sales in excess of $8 billion, Watson says. Watson first announced its plans to acquire Actavis last April. The combined company has global and US headquarters at Parsippany, and international headquarters at Zug. Watson says it will adopt...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee